← Product Code LOK · P980041

# ACCESS AFP IMMUNOASSAY SYSTEM (P980041)

_Beckman Coulter, Inc. · LOK · Feb 8, 1999 · Immunology · APPR_

**Canonical URL:** https://fda.innolitics.com/device/P980041

## Device Facts

- **Applicant:** Beckman Coulter, Inc.
- **Product Code:** LOK
- **Decision Date:** Feb 8, 1999
- **Decision:** APPR
- **Device Class:** Class 3
- **Review Panel:** Immunology

## Indications for Use

The Access® AFP assay is a paramagnetic particle, chemiluminescent immunoassay for use with the Access® Immunoassay System for the quantitative determination of alpha-fetoprotein (AFP) in: 1. Human serum, as an aid in the management of patients with non-seminomatous testicular cancer. 2. Maternal serum and amniotic fluid at 15 to 20 weeks gestation, to aid in the detection of fetal open neural tube defects (ONTD). The assay is intended for use in conjunction with other diagnostic tools such as ultrasound and amniography.

## Device Story

Access® AFP Immunoassay System is a benchtop, microcomputer-controlled analyzer for quantitative AFP measurement. Input: maternal serum or amniotic fluid samples. Principle: two-site immunoenzymatic (sandwich) assay using paramagnetic particles coated with monoclonal anti-human AFP antibody and alkaline phosphatase anti-human AFP antibody conjugate. Process: simultaneous incubation (4.8 min), magnetic separation, washing, and addition of chemiluminescent substrate (Lumi-Phos® 530). Output: light signal measured by luminometer, proportional to AFP concentration, calculated via stored multi-point calibration curve. Used in clinical laboratories by trained personnel. Results, combined with ultrasound/amniography, aid clinicians in identifying fetal ONTD risk or managing testicular cancer. Benefits: provides objective quantitative data to support diagnostic decisions for congenital malformations or cancer monitoring.

## Clinical Evidence

Multicenter, retrospective clinical trial (3 sites, N=3,737 samples). Evaluated maternal serum (N=2,924) and amniotic fluid (N=813) at 15-20 weeks gestation. Primary endpoints: diagnostic sensitivity and specificity for ONTD. Maternal serum sensitivity (≥2.0 MoM) was 91.3% (95% CI: 70.5%-98.5%); specificity (≥2.0 MoM) was 95.4%. Amniotic fluid sensitivity (≥3.0 MoM) was 100%. Method correlation with predicate showed high agreement (r=0.989 for serum, r=0.966 for amniotic fluid).

## Technological Characteristics

Paramagnetic particle, chemiluminescent immunoassay. Reagents: monoclonal anti-human AFP antibodies (IgG1, kappa). Detection: luminometer measuring light from dephosphorylated Lumi-Phos® 530. System: benchtop, microcomputer-controlled, random/continuous access analyzer. Modules: sample/reagent carousel, pipettor, analytical, fluidics, electronics. Connectivity: optional LIS communication.

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a PMA](https://innolitics.com/services/regulatory/), [a 510(k)](https://innolitics.com/services/510ks/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

Beckman Coulter, Inc.                                                                 Premarket Application Confidential                                                                 Access® AFP

# SECTION III: COMPREHENSIVE SUMMARY OF SAFETY AND EFFECTIVENESS

## I. General Information

**Device Generic Name:** Chemiluminescent immunoassay for *in vitro* diagnostic quantitation of alpha fetoprotein (AFP) in maternal serum and amniotic fluid.

**Device Trade Name:** Access® AFP Immunoassay System

**Applicant’s Name and Address:**

Beckman Coulter, Inc.
1000 Lake Hazeltine Drive
Chaska, MN 55318

**Premarket Approval Application (PMA) Number:** P980041

**Date of Panel Recommendation:** Pursuant to section 515 (c)(2) of the act as amended by the Safe Medical Devices Act of 1990, this PMA was not the subject of an FDA Immunology Advisory Panel meeting because the information in the PMA substantially duplicates information previously reviewed by this panel.

**Date of Notice of Approval to the Application:** FEB - 8 1999

## II. Intended Use

The Access® AFP assay is a paramagnetic particle, chemiluminescent immunoassay for use with the Access® Immunoassay System for the quantitative determination of alpha-fetoprotein (AFP) in:

1. Human serum, as an aid in the management of patients with non-seminomatous testicular cancer.
2. Maternal serum and amniotic fluid at 15 to 20 weeks gestation, to aid in the detection of fetal open neural tube defects (ONTD). The assay is intended for use in conjunction with other diagnostic tools such as ultrasound and amniography.

## Background

Open neural tube defects (ONTD) are among the most common and serious congenital malformation affecting approximately 1 to 2 newborns per 1000 births in the United States (1).

Page 1

{1}

Beckman Coulter, Inc.                                                                 Premarket Application Confidential                                                                 Access® AFP

Alpha-fetoprotein (AFP) is a feto-specific protein consisting of a single polypeptide chain with a molecular weight of approximately 70,000 Daltons, slightly larger than albumin. Unlike albumin, AFP is a glycoprotein containing approximately 4% carbohydrate and is, after albumin, the major protein in fetal circulation (2). Production occurs primarily in the fetal liver and to a lesser degree in the yolk sac and other fetal organs (3). AFP is secreted into the fetal serum where it is detectable approximately 30 days after conception (4). Fetal serum concentrations of AFP peak at the end of the first trimester then gradually decrease during later gestation (5).

During gestation, AFP is present in the amniotic fluid as a result of fetal micturition. AFP reaches the maternal circulation via the placenta or by diffusion across the fetal membranes. Measurable concentrations appear in the maternal serum beginning at the end of the first trimester reaching a maximum level during the second trimester.

The presence of AFP in maternal sera was recognized by Seppala and Ruoslahti in 1972 (6). In that same year, Brock and Sutcliffe reported the association between increased amounts of AFP in the amniotic fluid and pregnancies affected with neural tube defects (7). The following year Brock, et al. demonstrated that AFP concentrations in maternal serum were also elevated under these conditions (8).

Increased AFP concentrations in maternal serum may occur in multiple fetuses, low birth weight and fetal demise. An incorrect estimation of gestational age may also lead to misinterpretation of the Multiple of the Median (MoM) result. Ultrasonography can be used to aid in the determination of gestational age, the presence of multiple fetuses, open neural tubes, or other pregnancy problems.

Prenatal measurement of AFP concentrations are an effective aid to identify women potentially at risk for carrying a fetus with an ONTD. Two United Kingdom Collaborative studies have demonstrated the overall reliability of AFP testing for the prenatal detection of ONTD; the first in 1977 addressed AFP maternal serum testing (12) and the second addressed amniotic fluid AFP testing (13).

Page 2                                                                 8

{2}

Beckman Coulter, Inc.                                                                 Premarket Application Confidential                                                                 Access® AFP

### III. Device Description

The Access® AFP reagents and the Access® Immunoassay Analyzer comprise the Access® Immunoassay System for the quantitative determination of AFP. The Access® AFP assay is a paramagnetic particle, chemiluminescent immunoassay for use with the Access® Immunoassay System for the quantitative determination of alpha-fetoprotein (AFP) in maternal human serum and amniotic fluid at 15 and 20 weeks of gestation, to aid in the detection of fetal open neural tube defects (ONTD). Maternal serum and amniotic fluid test results, when used in conjunction with ultrasonography, or amniography, and amniotic fluid acetylcholinesterase testing, aid in the detection of fetal ONTD.

The Access® AFP assay is a two-site immunoenzymatic (sandwich) assay that measures AFP concentrations between approximately 0.50 and 3000 ng/ml (0.40 and 2478 IU/ml). Prior to assaying, amniotic fluid samples require a dilution of 1 volume sample with 10 volumes of Access® AFP Sample Diluent. The assay features a simultaneous format in which the sample is incubated for 4.8 minutes at a controlled temperature with paramagnetic particles coated with monoclonal anti-human AFP antibody and alkaline phosphatase anti-human AFP antibody conjugate.

Separation in a magnetic field, and washing, removes materials not bound to the solid phase. A chemiluminescent substrate, Lumi-Phos® 530, is added to the reaction vessel and light generated by the dephosphorylation of the substrate is measured with a luminometer. The light production is proportional to the quantity of AFP in the sample. The quantity of AFP in the sample is determined by means of a stored, multi-point calibration curve.

### Access® Analyzer

The Access® Immunoassay Analyzer is a bench top, microcomputer controlled, random and continuous access instrument. The analyzer performs enzyme immunoassays utilizing paramagnetic particle solid phase and chemiluminescent detection. The Access® Immunoassay Analyzer consists of the following functional modules:

- Sample / Reagent Carousel Module
- Main Pipettor Module

Page 3                                                                 9

{3}

Beckman Coulter, Inc.                                                                 Premarket Application Confidential                                                                 Access® AFP

Analytical Module
Fluidics Module
Electronics / System Computer
Peripheral Module

The Access® Immunoassay Analyzer system software controls all instrument functions:

- Facilitates operator input through user interface
- Schedules assays
- Runs assays
- Monitors and controls environment within the instrument
- Drives instrument motors, valves, and hardware modules
- Stores data in data base files
- Facilitates Laboratory Information System (LIS) communication, optional

**WARNINGS AND PRECAUTIONS:**

Warnings and precautions for use of the device are stated in the attached product labeling. (See labeling)

## IV. Alternative Practices and Procedures

Alternative and additional practices or procedures for aiding in the detection of fetal ONTD *in utero* include ultrasonography and amniography. In addition, there are other AFP immunological *in vitro* diagnostic devices for which there are approved PMAs for use as an aid in the detection of fetal ONTD.

## V. Marketing History

The Access® AFP Immunoassay System, has been marketed in the US as an aid in the management of patients with non-seminomatous testicular cancer since September 1998.

## VI. Potential Adverse Effects of the Device on Health

As with any *in vitro* diagnostic device, a possible adverse effect may be either a false positive or false negative result.

In the event of an initial positive result, confirmatory testing is recommended in the package insert. In order for a false positive result to be reported (incorrect

Page 4
10

{4}

Beckman Coulter, Inc.                                                                 Premarket Application Confidential                                                                 Access® AFP

diagnosis of an ONTD), the confirmatory test would have to report a positive result which would also be incorrect.

In the event of a false negative report, a fetal abnormality would not be detected because no further testing would be done and the pregnancy outcome could potentially be a birth with an ONTD condition.

## VII. Summary of Studies

### A. Pre-Clinical Studies

Pre-Clinical studies were conducted at Beckman Coulter–Chaska to determine the purity and specificity of the reagents, as well as the performance characteristics of the assay.

#### Characterization of the Antigen

The AFP antigen used as the immunogen in the development of the monoclonal antibodies found in the Access® AFP assay was purified from human placenta. The AFP used to prepare the calibrators and controls for the Access® AFP assay was manufactured from human cord serum.

#### Characterization of the Antibodies

The antibodies chosen were characterized using the following tests:

- SDS-PAGE - the molecular weight of both purified monoclonal antibodies was determined to be 150 kD.
- Isoelectric focusing - the isoelectric points of each monoclonal antibody were determined. The isoelectric points for the monoclonal antibodies were pI = 6.2 – 6.6 for the capture antibody and pI = 6.5 – 6.9 for the conjugate antibody.
- Immunoglobulin subtyping by ELISA - the subtypes of the selected monoclonal antibodies were heavy chain IgG₁ and light chain K for both antibodies.
- Western Blot analysis - one band was observed against amniotic fluid and placental AFP, with no reactivity observed towards CEA or HSA with both antibodies.

Page 5

{5}

Beckman Coulter, Inc.
Premarket Application Confidential
Access® AFP

# Performance Characteristics

## 1. Reproducibility

Within-run, between-run and total reproducibility (precision) of the Access® AFP assay were determined at Beckman Coulter-Chaska. Three serum based controls containing AFP concentrations spanning the assay range were assayed in triplicate twice a day for 20 days. One kit lot was used in the testing. The summary of results are presented in Table 1. The percent coefficients of variation ranged from 3.41 to 4.44.

Table 1. Intra-assay (Within-run), Inter-assay (Between-run) and Total Precision

|  Sample | Grand Mean (n = 120) (ng/ml) | Within Run 1 SD | Within Run (%CV) | Between run 1 SD | Between Run %CV | Total 1 SD | Total (%CV)  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  1 | 6.53 | 0.21 | 3.22 | 0.21 | 3.22 | 0.29 | 4.44  |
|  2 | 72.10 | 2.08 | 2.88 | 1.47 | 2.04 | 2.55 | 3.54  |
|  3 | 1672.88 | 45.34 | 2.71 | 34.55 | 2.07 | 57.00 | 3.41  |

## 2. Analytical Sensitivity

The analytical sensitivity, or minimum detectable concentration (MDC), of the Access® AFP assay is defined as that concentration of AFP that corresponds to the relative light unit (RLU) that is 2 standard deviations greater than the mean RLU of 25 determinations of the Access® AFP Calibrator S0.

The analytical sensitivity was determined by assaying the Access® AFP Calibrator S0 in replicates of 25 in 9 assays using 3 different reagent lots. The mean value of all of the calculated sensitivities (from the 9 separate assays) was 0.06 ng/ml which is below the product labeling claim of 0.50 ng/ml of AFP.

## 3. Dilution Recovery

Three maternal serum samples and 5 amniotic fluid samples containing elevated concentrations of AFP were diluted using the Access® AFP Sample Diluent to yield several concentrations. Each dilution study was analyzed by means of linear regression, yielding correlation coefficients of 1.000 for all 3 maternal serum samples and 0.977 to 1.000 for amniotic fluid samples.

Page 6
12

{6}

Beckman Coulter, Inc.
Premarket Application
Confidential
Access® AFP

# 4. Cross Reactivity and Interfering Substances(Specificity)

The analytical specificity of the Access® AFP assay was evaluated with the substances listed in Table 2. Each of these substances was added to the calibrator matrix containing no AFP (control) and to calibrator matrix containing AFP (test). Each control and test sample was assayed in quadruplicate. The results of the interfering substances analysis demonstrate that there is no significant interference from any of the substances tested.

Table 2. Cross Reactivity and Interfering Substances Tested

|  Substance | Concentration  |
| --- | --- |
|  Bilirubin | 25 mg/dl  |
|  Hemoglobin | 1.2 g/dl  |
|  Triglycerides | 520 mg/dl  |
|  Albumin (BSA) | 6 mg/dl  |
|  Rheumatoid Factor | 600 IU/ml  |
|  Acetaminophen | 1500 μg/ml  |
|  Acetylsalicylic Acid | 10 mg/ml  |
|  Alpha-1-Acid
Glycoprotein | 4.54 mg/ml  |
|  Alpha-1-antitrypsin | 14.8 mg/ml  |
|  Ascorbic Acid | 1000 μg/ml  |
|  Bleomycin | 100 μU/ml  |
|  CEA | 375 μg/ml  |
|  Chlorothiozide | 1000 μg/ml  |
|  Cisplatin | 1000 μg/ml  |
|  Cobalamin | 500 μg/ml  |
|  Diazepan | 50 μg/ml  |
|  Ethyl Alcohol | 1.90%  |
|  Fetal Hemoglobin | 500 μg/ml  |
|  Haptoglobin | 500 mg/ml  |
|  HCG | 200 μg/ml  |
|  HFSH | 2 IU/ml  |
|  HLH | 2 IU/ml  |
|  HTSH | 6 μg/ml  |
|  Phenacetin | 500 μg/ml  |
|  Phenothizine | 150 μg/ml  |
|  Placental Lactogen | 100 μg/ml  |
|  Reserpine | 100 μg/ml  |
|  Retinoic Acid | 500 μg/ml  |
|  Riboflavin | 50 μg/ml  |
|  Spironolactone | 15 μg/ml  |
|  Thiamine HCl | 50 μg/ml  |
|  Transferrin | 23.7 mg/ml  |
|  Vinblastine | 500 μg/ml  |

Page 7
13

{7}

Beckman Coulter, Inc.
Premarket Application Confidential
Access® AFP

## 5. Stability

Three lots of Access® AFP reagents were stored between 2 and 10°C and were tested at specified time intervals. The results of this testing support expiration dating of at least 18 months.

## 6. Method Correlation

To determine the correlation between the Access® AFP and another AFP assay for which there is an approved PMA, a total of 437 maternal serum and 307 amniotic fluid samples were analyzed. Samples were run at 3 external sites and each site utilized 3 Access® AFP reagent kit lots. The data, presented in Table 3, demonstrate correlation between the Access® AFP and the other AFP assay.

Table 3. Access® AFP assay correlation.

|  Sample type | N | Range of Observations | Intercept | Slope | Correlation Coefficient  |
| --- | --- | --- | --- | --- | --- |
|  Maternal Serum | 437 | 3.06 – 268.56 ng/ml | 3.69 ng/ml | 0.86 | 0.989  |
|  Amniotic Fluid | 307 | 1.38 – 32.96 μg/ml | 0.38 μg/ml | 0.85 | 0.966  |

## B. Clinical Study

A multicenter, retrospective clinical trial was conducted to evaluate the safety and effectiveness the Access® AFP assay when used in conjunction with ultrasonography, or amniography to aid in the detection of fetal open neural tube defects in maternal serum and amniotic fluid at 15 to 20 weeks gestation.

### 1. Study Sites

The study was performed at 3 well-established, geographically diverse AFP testing centers in North America. The principal investigators and their institutions are shown in Table 4.

Page 8
14

{8}

Beckman Coulter, Inc.
Premarket Application Confidential
Access® AFP

Table 4. Study Sites and Principal Investigators

|  Site No. | Institution | Abbr. | Principal Investigators | Lab Certifications  |
| --- | --- | --- | --- | --- |
|  1 | Pavilion- St. Francois d' Assise (CHUQ)
Quebec City, Quebec, Canada | QUEBEC | Jean-Claude Forest, MD, Ph.D., FRCPC Biochimistre | Canadian Council  |
|  2 | Foundation for Blood Research
Scarborough, ME | FBR | George Knight, Ph.D.
Director, Prenatal Screening Laboratory | CLIA  |
|  3 | University of Texas Southwestern Medical Center
Dallas, TX | UTSMC | Leland Baskin, MD
Associate Professor, Dept. of Pathology
Frank H. Wians, Jr. Ph.D.
Associate Professor, Dept. of Pathology | CLIA and CAP  |

## 2. Study Objective

The clinical trial study objective was to:

- Establish median AFP values for amniotic fluid samples obtained from pregnant women at 15 through 20 weeks gestation with subsequent viable, unaffected singleton pregnancy outcomes
- Determine the diagnostic sensitivity and specificity, and their 95% confidence intervals for the Access® AFP assay
- Compare the Access® AFP assay to another AFP assay for which there is an approved PMA, utilizing both maternal serum and amniotic fluid samples
- Determine the performance characteristics (precision, linearity, and analytical sensitivity) of the Access® AFP assay in a clinical prenatal testing environment.

## 3. Subject Selection, Exclusion Criteria, and Study Population

Each site selected maternal serum and amniotic fluid samples from their laboratory AFP specimen storage bank utilizing a selection process that insured an unbiased population of maternal serum and amniotic fluid samples that met the inclusion and exclusion criteria. All subjects meeting the inclusion and exclusion criteria over the specified period were enrolled in the study.

The inclusion criteria were: 1) maternal serum samples obtained from pregnant women at 14 through 21 weeks gestation and who elected to

Page 9
15

{9}

Beckman Coulter, Inc.
Premarket Application
Confidential
Access® AFP

have AFP testing done as part of their obstetrical care; 2) amniotic fluid samples obtained from pregnant women at 15 through 21 weeks of gestation and who elected to have AFP testing done as part of their obstetrical care; and 3) the samples were stored in a continuous state (-20° C or colder), frozen less than 4 years in tightly sealed containers, and subjected to a maximum of one freeze-thaw cycle.

The exclusion criteria included: 1) the amniocentesis was performed prior to drawing the serum sample; 2) the serum samples were hemolyzed, icteric or lipemic; or 3) the amniotic fluid samples were visibly contaminated with blood.

Table 5 lists the number of samples included in this study.

Table 5. Study Population

|  Outcome | Weeks | Number of
Maternal Serum
Samples | Number of
Amniotic Fluid
Samples | Total Number
of Case Report
Forms  |
| --- | --- | --- | --- | --- |
|  Normal | 15 – 20 | 2,539 | 720 | 3,259  |
|   |  14 & 21 | 328 | 55 | 383  |
|  Multiple Birth | 14 –21 | 17 | 2 | 19  |
|  Abnormal | 14 - 21 | 40 | 36 | 76  |
|  All | 14 – 21 | 2,924 | 813 | 3,737  |

## 4. Study Results

The 3 clinical sites assayed a total of 2539 maternal serum and 720 amniotic fluid specimens with confirmed normal singleton pregnancies at 15 to 20 gestational weeks. Table 6 contains the combined maternal serum AFP regressed medians (ng/mL) for all three clinical sites.

Table 6
Maternal Serum AFP Medians
Quebec, FBR, UTSMC Combined

|  Gestational Week | Number of
Observations | Median
(ng/mL) | Multiple
Of Median
(2.0) | Multiple
Of Median
(2.5) | Multiple
Of Median
(3.0)  |
| --- | --- | --- | --- | --- | --- |
|  15 | 435 | 31.1 | 62.2 | 77.8 | 93.4  |
|  16 | 506 | 36.0 | 72.0 | 90.0 | 108.0  |
|  17 | 452 | 41.6 | 83.2 | 104.1 | 124.9  |
|  18 | 425 | 48.1 | 96.3 | 120.3 | 144.4  |
|  19 | 413 | 55.7 | 111.3 | 139.2 | 167.0  |
|  20 | 308 | 64.4 | 128.8 | 161.0 | 193.2  |

Page 10
16

{10}

Beckman Coulter, Inc.
Premarket Application
Confidential
Access® AFP

The Table 7 below contains the combined amniotic fluid AFP regressed medians (ng/mL) for all three clinical sites.

Table 7
Amniotic Fluid AFP Medians
Quebec, FBR, UTSMC Combined

|  Gestational Week | Number of Observations | Median (ng/mL) | Multiple Of Median (2.0) | Multiple Of Median (2.5) | Multiple Of Median (3.0)  |
| --- | --- | --- | --- | --- | --- |
|  15 | 157 | 16.5 | 33.0 | 41.3 | 49.5  |
|  16 | 107 | 13.4 | 26.9 | 33.6 | 40.3  |
|  17 | 105 | 10.9 | 21.8 | 27.3 | 32.8  |
|  18 | 117 | 8.9 | 17.8 | 22.2 | 26.6  |
|  19 | 111 | 7.2 | 14.4 | 18.1 | 21.7  |
|  20 | 123 | 5.9 | 11.7 | 14.7 | 17.6  |

Clinical specificity, defined as the probability that the test will be negative in the absence of disease is shown in tables 8 and 9.

Table 8
Clinical Specificity of the Access® AFP Assay for Maternal Serum
All sites combined

|  Gestational Week | Number of Samples | 2.0 MoM (%) | 2.5 MoM (%) | 3.0 MoM (%)  |
| --- | --- | --- | --- | --- |
|  15 | 435 | 92.6 | 97.2 | 99.3  |
|  16 | 506 | 95.3 | 98.2 | 98.8  |
|  17 | 452 | 95.1 | 98.0 | 98.9  |
|  18 | 425 | 96.7 | 98.8 | 99.5  |
|  19 | 413 | 96.4 | 98.8 | 99.8  |
|  20 | 308 | 96.4 | 98.7 | 99.7  |

Using a cutoff of 2.0 MoM for the maternal serum specimens from the 3 clinical sites, the clinical specificity was 95.4% (2421/2539) with a 95% confidence interval of 94.4% - 96.1%. Using a cutoff of 2.5 MoM for the maternal serum specimens, the clinical specificity was 98.3% (2495/2539) with a 95% confidence interval of 97.7% - 98.7%.

Table 9
Clinical Specificity of the Access® AFP Assay for Amniotic Fluid
All sites combined

|  Gestational Week | Number of Samples | 2.0 MoM (%) | 2.5 MoM (%) | 3.0 MoM (%)  |
| --- | --- | --- | --- | --- |
|  15 | 157 | 99.4 | 99.4 | 99.4  |
|  16 | 107 | 97.2 | 99.1 | 99.1  |
|  17 | 105 | 98.1 | 100.0 | 100.0  |
|  18 | 117 | 97.4 | 98.3 | 98.3  |
|  19 | 111 | 96.4 | 97.3 | 99.1  |
|  20 | 123 | 95.9 | 98.4 | 100.0  |

{11}

Beckman Coulter, Inc.
Premarket Application
Access® AFP
Confidential

Using a cutoff of 3.0 MoM for the amniotic fluid samples from the 3 clinical sites, the clinical specificity was 99.3% (715/720) with a 95% confidence interval of 98.3% - 99.7%.

Clinical sensitivity is defined as the probability that the test will be positive in the presence of an ONTD. The following tables summarize the clinical sensitivity of maternal serum AFP and amniotic fluid AFP.

Table 10
Clinical Sensitivity of the Access® AFP Assay for Maternal Serum
All sites combined

|  Category | Number of Defects | ≥ 2.0 Mom | ≥ 2.5 Mom | ≥ 3.0 Mom  |
| --- | --- | --- | --- | --- |
|  ONTD Affected Outcome | 23 | 91.3% | 73.9% | 69.6%  |
|  95% Confidence Interval |  | (70.5%-98.5%) | (51.3%-88.9%) | (47.0%-85.9%)  |

A total of 23 maternal serum specimens tested at the 3 clinical sites were associated with confirmed ONTD birth outcomes. Using a cutoff of 2.0 MoM, the clinical sensitivity of the Access® AFP assay for maternal serum was 91.3% (21/23) with a 95% confidence interval of 70.5% - 98.5%. Using a cutoff of 2.5 MoM for the maternal serum specimens, the clinical sensitivity was 73.9% (17/23) with a 95% confidence interval of 51.3% - 88.9%.

A total of 15 amniotic fluid specimens were associated with confirmed ONTD birth outcomes. Using a cutoff of 3.0 MoM, the clinical sensitivity of the Access® AFP assay for amniotic fluid was 100% (15/15).

Table 11
Clinical Sensitivity of the Access® AFP Assay for Amniotic Fluid
All sites combined

|  Category | Number of Defects | ≥ 2.0 Mom | ≥ 2.5 Mom | ≥ 3.0 Mom  |
| --- | --- | --- | --- | --- |
|  ONTD Affected Outcome | 15 | 100.0% | 100.0% | 100.0%  |

## VIII. Conclusions Drawn from Studies

Study results demonstrate that the Access® AFP assay is safe and effective when used in conjunction with ultrasonography, or amniography, to aid in the

Page 12
18

{12}

Beckman Coulter, Inc.                                                                 Premarket Application Confidential                                                                 Access® AFP

detection of fetal open neural tube defects in maternal serum and amniotic fluid at 15 to 20 weeks gestation.

## IX. Panel Recommendation

Pursuant to section 515 (c)(2) of the act as amended by the Safe Medical Devices Act of 1990, this PMA was not the subject of an FDA Immunology Advisory Panel meeting because the information in the PMA substantially duplicates information previously reviewed by this panel.

## X. CDRH Action on the Application

CDRH issued an approval order for the applicant’s PMA Access® AFP Immunoassay System on February 8, 1999.

The applicant’s manufacturing and control facilities were inspected on January 25, 1999 and the facilities were found to be in compliance with the Good Manufacturing Practice Regulations (GMPs). The shelf-life of Access® AFP Immunoassay System has been established at 18 months for product stored between 2° and 10° C.

## XI. Approval Specifications

Directions for Use: See labeling

Conditions of Approval: FDA approval of this PMA is subject to full compliance with the conditions described in the approval order.

Page 13

{13}

Beckman Coulter, Inc.                                                                 Premarket Application Confidential                                                                 Access® AFP

# XIII. References

1. Macri JN, Baker DA, and Baim RS. Diagnosis of neural tube defects by evaluation of amniotic fluid. Clin Obstet Gynecol 1981; 24: 1089.

2. Ruoslahti E, Seppala M. Studies of carcino-fetal proteins: Physical and chemical properties of human alpha-fetoprotein. Int J Cancer 1971; 7: 218.

3. Gitlin D, Perricelli A, Gitlin GM. Synthesis of alpha-fetoprotein by liver, yolk sac, and gastrointestinal tract of the human conceptus. Cancer Res 1972; 32: 979.

4. Crandall BF. Alpha-fetoprotein: The diagnosis of neural tube defects. Ped Annals 1981; 10: 78.

5. Kjessler B, Johansson SGO. Monitoring of the development of early pregnancy by determination of alpha-fetoprotein in maternal serum and amniotic fluid samples. Acta Obstet Gynecol Scand 1977; 69: 5.

6. Seppala M, Ruoslahti E. Radioimmunoassay of maternal serum alpha-fetoprotein during pregnancy and delivery. Am J Obstet Gynecol 1972; 112: 208.

7. Brock DJH and Sutcliffe RG. Alpha-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida. Lancet 1972; 2(7770): 197.

8. Brock DJH, Bolton AE, Monaghan JM. Prenatal diagnosis of anencephaly through maternal serum alpha-fetoprotein measurements. Lancet 1973; 2(7835): 923.

9. Smith AD, Wald NJ, Cuckle HS, Stirrat GM, Bobrow M, Lagercrantz H. Amniotic fluid acetylcholinesterase as a possible diagnostic test for neural tube defects in early pregnancy. Lancet 1979; 1(8118): 685.

10. Macri JN and Weiss RR. The utilization of alpha-fetoprotein in prenatal diagnosis. Birth Defects 1977; 13: 191.

11. Macri JN, Haddow JE, Weiss RR. Screening for neural tube defects in the United States: A summary of the Scarborough Conference. Am J Obstet Gynecol 1979; 133: 119.

12. Wald NJ, Cuckle H, Brock JH, Peto R, Polani PE, Woodford FP. Maternal serum alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of UK Collaborative Study on Alpha-fetoprotein in Relation to Neural Tube Defects. Lancet 1977; 1(8026): 1323.

13. Amniotic fluid alpha-fetoprotein measurement in antenatal diagnosis of anencephaly and open spina bifida in early pregnancy. Second Report of the UK Collaborative Study on Alpha-fetoprotein in Relation to Neural Tube Defects. Lancet 1979; 2(8144): 651.

Page 14                                                                 20

---

**Source:** [https://fda.innolitics.com/device/P980041](https://fda.innolitics.com/device/P980041)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a PMA](https://innolitics.com/services/regulatory/), [a 510(k)](https://innolitics.com/services/510ks/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com